​

Century Therapeutics (IPSC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IPSC Stock Forecast

Century Therapeutics (IPSC) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $5.00, with a high of $5.00 and a low of $5.00. This represents a 825.93% increase from the last price of $0.54.

- $1 $2 $3 $4 $5 High: $5 Avg: $5 Low: $5 Last Closed Price: $0.54

IPSC Stock Rating

Century Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

IPSC Price Target Upside V Benchmarks

TypeNameUpside
StockCentury Therapeutics825.93%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$5.00
Last Closing Price$0.54$0.54$0.54
Upside/Downside--825.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25231--6
Mar, 25231--6
Feb, 25241--7
Jan, 25241--7
Dec, 24241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Mitchell KapoorH.C. Wainwright$5.00$1.39259.71%825.93%
Apr 12, 2024Edward TenthoffPiper Sandler$9.00$4.05122.22%1566.67%
Jan 05, 2023Edward TenthoffPiper Sandler$14.00$4.84189.26%2492.59%
Dec 27, 2022Geulah LivshitsChardan Capital$19.00$5.67235.10%3418.52%
Nov 14, 2022H.C. Wainwright$25.00$11.00127.27%4529.63%
Apr 29, 2022Leerink Partners$27.00$12.03124.44%4900.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 15, 2024H.C. WainwrightBuyBuyhold
Aug 08, 2024Rodman & RenshawBuyinitialise
Jun 17, 2024Piper SandlerOverweightOverweighthold
Jun 04, 2024Piper SandlerBuyBuyhold
Apr 12, 2024Piper SandlerOverweightOverweighthold
Aug 28, 2023NeedhamNeutraldowngrade
Aug 10, 2023Chardan CapitalBuyBuyhold
Jan 06, 2023SVB LeerinkOutperformOutperformhold
Jan 05, 2023Piper SandlerOverweightOverweighthold
Dec 27, 2022Chardan CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.27$-2.30$-1.61----
Avg Forecast$-2.31$-2.17$-1.60$-1.76$-1.50$-2.09$-1.99
High Forecast$-0.18$-1.86$-1.42$-1.43$0.26$0.36$0.34
Low Forecast$-5.20$-2.35$-1.71$-1.99$-3.88$-5.40$-5.14
Surprise %-1.73%5.99%0.63%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.20M$2.23M$6.59M----
Avg Forecast$6.69M$3.65M$3.17M$3.26M$3.95M$13.75M$153.10M
High Forecast$13.14M$6.60M$4.11M$6.75M$3.98M$30.49M$339.52M
Low Forecast$1.95M$1.67M$2.35M$300.00K$3.92M$1.36M$15.09M
Surprise %-22.29%-38.68%108.07%----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-130.93M$-136.67M$-126.57M----
Avg Forecast$-136.89M$-136.67M$-92.87M$-101.58M$-199.36M$-123.97M$-118.04M
High Forecast$-10.69M$-110.43M$-84.16M$-84.85M$15.33M$21.31M$20.29M
Low Forecast$-308.44M$-139.26M$-101.57M$-118.31M$-230.33M$-320.20M$-304.88M
Surprise %-4.36%-36.29%----

IPSC Forecast FAQ

Is Century Therapeutics stock a buy?

Century Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Century Therapeutics is a favorable investment for most analysts.

What is Century Therapeutics's price target?

Century Therapeutics's price target, set by 8 Wall Street analysts, averages $5 over the next 12 months. The price target range spans from $5 at the low end to $5 at the high end, suggesting a potential 825.93% change from the previous closing price of $0.54.

How does Century Therapeutics stock forecast compare to its benchmarks?

Century Therapeutics's stock forecast shows a 825.93% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Century Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Century Therapeutics’s EPS forecast?

Century Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.76, marking a 9.32% increase from the reported $-1.61 in 2024. Estimates for the following years are $-1.5 in 2026, $-2.09 in 2027, and $-1.99 in 2028.

What is Century Therapeutics’s revenue forecast?

Century Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.26M, reflecting a -50.49% decrease from the reported $6.59M in 2024. The forecast for 2026 is $3.95M, followed by $13.75M for 2027, and $153.1M for 2028.

What is Century Therapeutics’s net income forecast?

Century Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-102M, representing a -19.75% decrease from the reported $-127M in 2024. Projections indicate $-199M in 2026, $-124M in 2027, and $-118M in 2028.